Legislation and official documents
Pricing of medicines from Belgium
The national health plan, presented at the beginning of July 2022, is aligned with the need to provide Luxembourg with the tools and platforms to allow innovations in the therapeutic field; IML is concerned about the dissonance between these principles and the realities encountered in the accessibility of innovative medicines by Luxembourg patients.
Since October 2021, as we were able to point out in our letters of January 7 and June 27 to the Ministers of Health and Social Security, the industry has been faced with the refusal of the MSS to specific requests for prices of medicines whose country of origin is Belgium. This hinders access to innovations for Luxembourg patients, who receive new treatments nine to twelve months late.
We invite you to take note of the second legal opinion that we sent to the MSS in June 2022, for which we did not receive any answer.
Would you like to become a member?
Would you like to exchange and share your expertise with nearly 60 innovative pharmaceutical companies, media partners and business partners?
Contact us at email@example.com